| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Medical and Surgical Sciences (F.F., E.C., F.M.), University of Padova; Unit Care of Angiology (G.C., G.M.A.), City Hospital of Padova; and Department of Surgical and Gastroenterological Sciences (F.L.), University of Padova, 35128 Padova, Italy
Address all correspondence and requests for reprints to: Francesco Fallo, M.D., Department of Medical and Surgical Sciences, Division of Medical Therapeutics, University of Padova, Via Ospedale 105, 35128 Padova, Italy. E-mail: francesco.fallo{at}unipd.it.
Patients with primary hyperparathyroidism (PHPT) have an increased cardiovascular morbidity and mortality. Elevated serum calcium and/or PTH may directly contribute to vascular tissue damage, but the role of classic factors for atherosclerosis has not fully been evaluated in this disease. The aim of our study was to dissect the potential effect of hypercalcemia and/or high PTH from that of major cardiovascular risk factors (i.e. diabetes mellitus, hyperlipidemia, hypertension, obesity, smoking habit) on the carotid artery structure of patients with PHPT. Twenty-six consecutive patients with PHPT [subdivided into two groups according to the absence (n = 10) or the presence (n = 16) of one or more risk factors] and 15 normocalcemic healthy subjects as controls were studied. At ultrasonography, a significant increase (P < 0.001) of carotid mean and maximum intima-media thickness, as well as a significant reduction of lumen diameter (P < 0.05) were found in the PHPT group with risk factors, compared with the other two groups. This suggests that hypercalcemia and/or PTH elevation per se are not determinant of carotid atherosclerosis in PHPT, and that increased cardiovascular mortality and morbility in this disease is attributable to the combined presence of classic cardiovascular risk factors.
Abbreviations: CI, Confidence intervals; BMI, body mass index; IMT, intima-media thickness; M-IMT, maximum IMT; m-IMT, mean IMT; NS, not significant; PHPT, primary hyperparathyroidism.
This article has been cited by other articles:
![]() |
C. Erem, M. Kocak, I. Nuhoglu, M. Yilmaz, and O. Ucuncu Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism Eur. J. Endocrinol., May 1, 2009; 160(5): 863 - 868. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Silverberg, E. M. Lewiecki, L. Mosekilde, M. Peacock, and M. R. Rubin Presentation of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 351 - 365. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Rubin, M. S. Maurer, D. J. McMahon, J. P. Bilezikian, and S. J. Silverberg Arterial Stiffness in Mild Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3326 - 3330. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Vryonidou, A. Papatheodorou, A. Tavridou, T. Terzi, V. Loi, I.-A. Vatalas, N. Batakis, C. Phenekos, and A. Dionyssiou-Asteriou Association of Hyperandrogenemic and Metabolic Phenotype with Carotid Intima-Media Thickness in Young Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2740 - 2746. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Andersson, E. Rydberg, and R. Willenheimer Primary hyperparathyroidism and heart disease -- a review Eur. Heart J., October 2, 2004; 25(20): 1776 - 1787. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |